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T follicular helper (Tfh) cells promote T cell-depen-
dent humoral immune responses by providing T cell
help to B cells and by promoting germinal center
(GC) formation and long-lived antibody responses.
However, the cellular and molecular mechanisms
that control Tfh cell differentiation in vivo are incom-
pletely understood. Here we show that interleukin-2
(IL-2) administration impaired influenza-specific
GCs, long-lived IgG responses, and Tfh cells. IL-2
did not directly inhibit GC formation, but instead
suppressed the differentiation of Tfh cells, thereby
hindering the maintenance of influenza-specific GC
B cells. Our data demonstrate that IL-2 is a critical
factor that regulates successful Tfh and B cell
responses in vivo and regulatesTfhcell development.
INTRODUCTION
The generation of long-lived plasma cells that secrete high-
affinity antibodies is critical for the establishment of protective
immunity to influenza and other pathogens. The selection of
long-lived B cells with high-affinity BCRs is dependent on events
that occur in the germinal center (GC) (Allen et al., 2007; Cyster,
2010; Kelsoe, 1996). GCs are structures found in the B cell folli-
cles of reactive lymphoid tissues and support intense B cell
clonal expansion, somatic hypermutation of immunoglobulin
genes, affinity maturation of the B cell response, and ultimately
the differentiation of both memory B cells and long-lived plasma
cells (Allen et al., 2007; Cyster, 2010; Vinuesa et al., 2010). Given
that the goal of most vaccination strategies is the generation of
long-lived antibody responses (Cox et al., 2004), it is essential
that we understand the factors that regulate GC formation and
maintenance.
GCs are dependent on help provided by CD4+ T follicular
helper (Tfh) cells—a recently defined CD4+ T cell subset with
a unique ability to help B cell responses (Crotty, 2011; Yu and
Vinuesa, 2010). B cells and Tfh cells provide each other with
reciprocal differentiation and survival signals (King, 2011). Tfh
cells provide CD40 ligand (Goodnow et al., 2010; Han et al.,
1995) and IL-21 to B cells (Bryant et al., 2007; Linterman et al.,
2010; Vogelzang et al., 2008) and B cells present antigen and
provide ICOS ligand to Tfh cells (Choi et al., 2011; Deenicket al., 2011; Johnston et al., 2009; Nurieva et al., 2009). As
a result, all three of these molecules are essential for germinal
center formation and long-lived antibody responses (Goodnow
et al., 2010). Importantly, the differentiation of Tfh cells depends
on the expression of the transcription factor Bcl6, which
represses the expression of other lineage-specific transcription
factors and promotes the expression of CXCR5 (Johnston
et al., 2009; Nurieva et al., 2009; Yu et al., 2009). In turn,
CXCR5 facilitates homing to the B cell follicle and germinal
center (Hardtke et al., 2005; Haynes et al., 2007). As a result,
Bcl6-deficient CD4+ T cells do not properly express CXCR5,
fail to migrate into B cell follicles, and do not to support GC reac-
tions. Thus, Bcl6 is considered the master regulator of Tfh cell
differentiation (Johnston et al., 2009; Nurieva et al., 2009; Yu
et al., 2009). However, the molecular mechanisms that regulate
Bcl6 expression and the differentiation of Tfh cells in vivo are
incompletely defined (Crotty, 2011; Yu and Vinuesa, 2010).
Recent results demonstrate that CD4+ T cells responding to
LCMV can be separated based on the expression of the inter-
leukin-2 receptor a (CD25) into CD25hi and CD25lo subsets
(Choi et al., 2011). Importantly, CD25hi T cells do not express
Bcl6, suggesting a possible role for IL-2 in the segregation of
effector and Tfh cells. IL-2 was originally defined as an essential
T cell growth factor that promotes expansion of effector T cells
and facilitates CD8+ memory T cell programming (Blattman
et al., 2003; Malek, 2008; Malek and Castro, 2010; Williams
et al., 2006). However, IL-2 signaling also controls the contrac-
tion of T cell responses by enhancing susceptibility of respond-
ing T cells to activation-induced cell death (Lenardo, 1991). IL-2
signaling through CD25 enhances CD25 expression and sensi-
tivity to IL-2 and also controls the expression of key transcription
factors, such as eomesodermin (Eomes), Blimp1, and Bcl6, in
CD8 T cells (Pipkin et al., 2010).
The generation and maintenance of FoxP3-expressing CD4+
regulatory T (Treg) cells are also dependent on IL-2 (Almeida
et al., 2002; de la Rosa et al., 2004; Malek and Castro, 2010;
Malek et al., 2002). Treg cells suppress the activation of autor-
eactive T cells, prevent the development autoimmune disease
(Campbell and Koch, 2011; Malek et al., 2002), and play an
important role in the control of B cell responses (Alexander
et al., 2011; Chung et al., 2011; Lim et al., 2004, 2005; Linterman
et al., 2011). Given the essential role for IL-2 in the maintenance
of Treg cells, some investigators are using IL-2 therapy to treat
autoimmune disease in mouse models (Grinberg-Bleyer et al.,
2010; Humrich et al., 2010). In humans, IL-2 therapy has been
used to enhance antitumor immunity (Kovacs et al., 2001;Immunity 36, 847–856, May 25, 2012 ª2012 Elsevier Inc. 847
Figure 1. IL-2 Inhibits B Cell Responses to
Influenza
B6 mice were infected with PR8 and treated with
30,000 U of human rIL-2 or PBS daily starting
3 days after infection.
(A) Serum was obtained on day 21 after infection
and titers of influenza-specific IgG1 were deter-
mined by ELISA.
(B) Influenza-specific IgG-secreting cells in the BM
were enumerated by ELISPOT on day 21 after
infection.
Data are representative of two independent
experiments (mean ± SD of five mice per group).
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IL-2 Limits Tfh Cell and Germinal Center FormationRosenberg et al., 1985a, 1985b), particularly in combination with
B cell depletion in the treatment of non-Hodgkin lymphoma
(Friedberg et al., 2002; Gillies et al., 2005; Gluck et al., 2004;
Lopes de Menezes et al., 2007). Thus, IL-2 may be used to treat
a variety of diseases.
Although IL-2 can modulate effector and Treg cell function by
a variety of mechanisms, the role of IL-2 in the control of B cell
and Tfh cell responses remain unclear. Here we tested the role
of IL-2 in the GC B cell response to influenza. We found that
IL-2 impaired the influenza-specific GC response, reduced the
influenza-specific IgG response, and prevented the accumula-
tion of influenza-specific Tfh cells. We demonstrated that IL-2
did not directly inhibit GCs, but instead directly suppressed Tfh
cell responses. We found that CD25 signaling triggered by IL-2
negatively modulated Bcl6 expression and Tfh cell development.
These data demonstrate that the physiological availability of IL-2
is a critical factor that regulates successful Tfh and B cell
responses in vivo.
RESULTS
IL-2 Treatment Impairs GC B Cell Formation and
Antibody Responses after Influenza Infection
To determine the role of IL-2 in the B cell response to influenza,
we infected C57BL/6 (B6) mice with influenza virus A/PR8/34
(PR8) and treated infected mice with 30,000 U of human re-
combinant IL-2 (rIL-2) or PBS twice a day starting 3 days
after infection. On day 21 postinfection, we collected sera from
rIL-2-treated and control mice and determined the titers of
influenza-specific IgG by ELISA (Figure 1A). We observed
a substantial reduction in influenza-specific IgG1 titers in the
rIL-2-treated group compared to control mice. To determine
whether rIL-2 treatment specifically blocked the generation of
influenza-specific IgG-secreting plasma cells that home to the
bone marrow (BM) and provide long-lasting immunity to influ-
enza, we enumerated influenza-specific IgG-secreting plasma
cells in the BM on day 21 postinfection by ELISPOT. In agree-
ment with the antibody titers, we found that the number of
IgG-secreting influenza-specific plasma cells in the bone
marrow was reduced in the BM of rIL-2-treated mice relative to
control mice (Figure 1B). Thus, our results indicate that rIL-2
treatment compromised influenza-specific humoral immune
responses.
Given that GC formation is required for the differentiation of
long-lived plasma cells (Johnston et al., 2009; Nurieva et al.,
2009; Vinuesa et al., 2010; Yu et al., 2009), we hypothesized848 Immunity 36, 847–856, May 25, 2012 ª2012 Elsevier Inc.that rIL-2 treatment may inhibit the formation of GCs after influ-
enza infection. To test this hypothesis, we infected B6 mice
with influenza and treated them with either rIL-2 or PBS. On
day 10 postinfection, we probed cryosections of mediastinal
lymph nodes (mLNs) with fluorochrome-labeled PNA and anti-
B220 to detect GCs. As expected, PNA+ GC structures were
easily detected in the B cell follicles of control mice. However,
although B cell follicles were present in rIL-2-treated mice,
PNA+ GC structures were virtually undetectable after rIL-2 treat-
ment (Figure 2A). Consistent with the histological results, the
frequency (Figure 2B) and number (Figure 2C) of CD19+
PNAhiFAS+ GC B cells were reduced in rIL-2-treated mice.
To determine whether the IL-2 treatment impaired the devel-
opment of influenza-specific GC B cell responses, we used fluo-
rochrome-labeled recombinant influenza nucleoprotein (NP)
tetramers to identify NP-specific PNAhiFAS+ GC B cells. We
found that rIL-2 treatment reduced the frequency of NP-specific
PNAhiFAS+ GC B cells by nearly 80% compared to control mice
(Figure 2D). In a control experiment, we demonstrated that the
NP B cell tetramer bound only B cells from influenza-infected
mice and not B cells from mice infected with other pathogens
(Figure S1 available online). Collectively, these data show that
the influenza-specific GC B cell response was severely compro-
mised in the presence of excess IL-2.
IL-2 Indirectly Suppresses the GC B Cell Response
to Influenza
To determine whether rIL-2 treatment acted directly on GC B
cells, we generated 50:50 mixed BM chimeras by using
B6.CD45.1 bonemarrow (BM) andCd25/BM (CD45.2). As ex-
pected, the cells that repopulated the chimeric mice were
derived equally from both donors (Figure 3A). We subsequently
infected the chimeric mice with influenza, administered either
rIL-2 or PBS, and determined the frequency of PNAhiFAS+ GC
cells within the B6 and Cd25/ CD19+ B cells on day 10. We
found that B6 (CD45.1) and Cd25/ (CD45.2) B cells contained
equal frequencies of GC B cells in both PBS-treated (Figure 3B)
and IL-2-treated (Figure 3C) mice. Although the GC B cell
response was diminished in the rIL-2-treated chimeras relative
to that in the PBS-treated mice (Figures 3B and 3C), the ratio
of B6 to Cd25/ GC B cells was close to 1.0 in both groups
(Figure 5D). We observed similar results when we examined
NP-specific GC B cell response of B6 and Cd25/ donors
(Figures 3E–3G). These results suggest that IL-2 inhibited the
development of GC B cells indirectly and not through a B cell-
intrinsic mechanism.
Figure 2. IL-2 Impairs GC B Cell Responses to
Influenza
(A) B6 mice were infected with PR8 and treated with
30,000 U of human recombinant rIL-2 or PBS twice a day
starting 3 days after infection. mLNs were obtained on day
10 after infection and cryosections were stained with anti-
B220 (blue) and PNA (red) and analyzed by fluorescent
microscopy.
(B and C) Cells from the mLNs of mice treated with IL-2 or
PBS were obtained on day 10 and the percentage of
CD19+ B cells with a PNA+FAS+ GC phenotype was
determined (B), and the number of GC B cells was calcu-
lated (C). Data are representative of four independent
experiments (mean ± SD of five mice per group).
(D and E) Cells from mLNs were obtained on day 10 after
infection and GC B cells were identified by flow cytometry
with an NP tetramer. The percentage of NP-specific B cells
with a PNA+FAS+ GC phenotype was determined (D) and
the number of NP-specific PNA+FAS+ CD19+ B cells was
calculated (E). Data are representative of three indepen-
dent experiments (mean ± SD of five mice per group).
All p valueswere determined by two-tailed Student’s t test.
See also Figure S1.
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IL-2 Limits Tfh Cell and Germinal Center FormationrIL-2 Suppresses the GC B Cell Response to Influenza
by a Treg Cell-Independent Mechanism
IL-2 signaling is crucial for the generation and maintenance of
FoxP3-expressing Treg cells (Almeida et al., 2002; de la Rosa
et al., 2004; Malek and Castro, 2010; Malek et al., 2002).
Corresponding with this idea, we found more Treg cells in influ-
enza-infected mice that were treated with rIL-2 than in control
mice (Figure 4A). Because Treg cells suppress B cell immune
responses, we next tested whether the inhibitory effect of rIL-2
treatment on GC formation was mediated by enhanced Treg
cell function. Therefore, we treated FoxP3-DTR mice (Kim
et al., 2007) with diptheria toxin (DT), infected themwith influenza
virus, and treated them with either rIL-2 or PBS. Treatment of
Foxp3-DTR mice with DT efficiently depleted FoxP3-expressing
cells even after rIL-2 administration (Figure 4A). Infected mice
were then administered rIL-2 on a daily basis, and we deter-
mined the frequency of PNAhiFAS+ GC cells within CD19+ B cells
on day 10 after infection. As expected, FoxP3-DTR treated with
rIL-2 alone had a decreased frequency (Figure 4B) and number
(Figure 4C) of GC B cells compared to untreated FoxP3-DTR
mice. Importantly, the frequency (Figure 4B) and number
(Figure 4C) of GC B cells were even more reduced in Treg cell-
depleted mice after rIL-2 treatment. As a control, DT administra-
tion to B6 mice did not affect the accumulation of GC B cell after
influenza infection (data not shown). Thus, these results indicateImmunity 36that rIL-2 inhibited GC B cell development by
a Treg cell-independent mechanism.
Treatment of Mice with rIL-2 Impairs Tfh
Cell Response
Tfh cells are required for the development and
maintenance of GCs (Johnston et al., 2009;
Nurieva et al., 2009; Yu et al., 2009). Because
GCs are dependent on Tfh cell help, we next
considered the possibility that the excess IL-2
compromised GC B cell formation by inhibitingthe development of Tfh cells. To test this possibility, we treated
influenza-infected B6 mice with influenza, treated them with
IL-2 or PBS, and enumerated Tfh cells in themLNonday 10 post-
infection. We characterized Tfh cells as PD-1hiCXCR5hi CD4+
T cells (Figure 5A, left) that expressed high levels of the transcrip-
tion factor Bcl6 and the costimulatory receptor ICOS compared
to non-Tfh cells (Figure 5A, right). Importantly, we found fewer
CD4+Tcells that expressedBcl6 after rIL-2 treatment (Figure 5B),
and both the frequency (Figure 5C) and number (Figure 5D) of
PD-1hiCXCR5hi Tfh cells were reduced relative to control mice.
To determine whether IL-2 was altering themaintenance of Tfh
cells or preventing their development, we performed a similar
experiment but examined the Tfh cell response on day 6, which
is as early as we can consistently detect Tfh cells by flow cytom-
etry. We found that IL-2 treatment between days 3 and 6 after
infection reduced both the frequency (Figure 5E) and number
(Figure 5F) of Tfh cells in the mLN. Thus, IL-2 acts early in the
process of Tfh cell development and probably suppresses the
commitment of primed CD4 T cells to the Tfh cell developmental
pathway.
To test whether rIL-2 treatment disrupted Tfh cells by affecting
the number of influenza-specific Tfh cells, we characterized the
influenza nucleoprotein (NP)-specific CD4+ T cell response by
using a fluorochrome-labeled MHC class II tetramer (Figure 5G).
We found that NP-specific CD4+ T cells could be divided into, 847–856, May 25, 2012 ª2012 Elsevier Inc. 849
Figure 3. rIL-2 Indirectly Inhibits GC B Cell Response to Influenza
B6 mice were irradiated and reconstituted with a 50:50 mix of BM from wild-type CD45.1 donors and Cd25/ donors (CD45.2).
(A) Percentage of leukocytes that expressed either CD45.1 or CD45.2 was determined in the mLN 8 weeks after reconstitution.
(B–D) Reconstituted mice were infected with PR8 and treated daily with 30,000 U of PBS (B) or rIL-2 (C) starting 3 days after infection, and the percentage of
CD45.1+ or CD45.2+ CD19+ B cells with a PNA+FAS+ GC phenotype was determined on day 10. The ratio of B6 to Cd25/ PNA+FAS+ CD19+ B cells was
calculated (D).
(E–G) Reconstituted mice were infected with PR8 and treated daily with 30,000 U of rIL-2 or PBS starting 3 days after infection, and on day 10 the percentage of
CD45.1+ or CD45.2+ NP-specific CD19+ B cells with a PNA+FAS+ GC phenotype was determined in the mLNs of mice treated with PBS (E) or with rIL-2 (F). The
ratio of B6 to Cd25/ PNA+FAS+ NP-specific CD19+ B cells was determined (G).
Data are representative of three independent experiments (mean ± SD of three to five mice per group). p values were determined by two-tailed Student’s t test.
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IL-2 Limits Tfh Cell and Germinal Center Formationa PD-1hiCXCR5hi population, which expressed high levels of
ICOS and Bcl6 (Tfh cells), and a PD-1loCXCR5lo population,
which expressed low levels of ICOS and Bcl6 (CD4+ effectors)
(Figure 5G). Interestingly, whereas NP-specific effector CD4+
T cells were CD25hi, NP-specific Tfh cells were CD25lo (Fig-
ure 5G), suggesting that these populations received quantita-
tively different signals from the IL-2 receptor. We also found
that IL-2 treatment reduced the frequency of NP-specific CD4+
T cells that expressed Bcl6 (Figure 5H) and that the frequency
(Figure 5I) and number (Figure 5J) of NP-specific Tfh cells were
reduced in IL-2-treated mice compared to control. In contrast,
rIL-2 treatment did not affect the accumulation of NP-specific
effector CD4+ T cells (Figure 5K). Given the reduced frequency
of Bcl6-expressing Tfh cells in IL-2-treated mice, we next deter-
mined whether those Tfh cells remaining also expressed
reduced amounts of Bcl6. We found that Bcl6 expression was
identical in CD4+CXCR5+PD-1hi cells from IL-2-treated and
control mice and in NP-specific CD4+CXCR5+PD-1hi cells from
IL-2-treated and control mice (Figure 5L). Taken together, these
results suggest that rIL-2 administration compromised the early
commitment to the Tfh cell lineage rather than affecting already
differentiated Tfh cells.
IL-2 Directly Suppresses the Tfh Cell Response to
Influenza
rIL-2 compromised the accumulation of Tfh cells, so we next
considered the possibility that rIL-2 acted directly on CD4+
T cells and inhibited Tfh cell development. To test this possibility,
we generated mixed BM chimeras that contained a 50:50 mix of
B6andCd25/cells.Twomonthsafter reconstitution,we infected850 Immunity 36, 847–856, May 25, 2012 ª2012 Elsevier Inc.the chimeric mice with influenza, administered rIL-2 or PBS, and
determined the frequency of Tfh cells within the B6 and Cd25/
compartments on day 10 after infection. We found a higher
frequency of Tfh cells in the Cd25/ compartment than in the B6
compartment (Figure 6A). Similar results were obtained when we
analyzed the frequency of NP-specific Tfh cells (Figure 6B). Thus,
these results indicated that rIL-2 acts directly on T cells to inhibit
Tfh cell development and that the lossof Tfh cells is the likely cause
of poor GC and antibody responses in rIL-2-treated mice.
The previous results suggested that CD25 signaling negatively
regulates Tfh cell development. If this was true, then we would
predict a higher frequency of Tfh cells in the Cd25/ CD4+
T cell population compared to the B6 counterparts—even in un-
treated mice. To test this hypothesis, we infected B6:Cd25/
mixed BM chimeras with influenza and calculated the frequency
of Tfh cells within the the B6 andCd25/ compartments 10 days
postinfection. We foundmoreCd25/ Tfh cells than B6 Tfh cells
when we looked at total Tfh cells (Figure 6C) and NP-specific Tfh
cells (Figure 6D). As a control, we also determined the relative
frequencies of CD45.1 and CD45.2 cells in the total CD4+
T cell compartment. We found that the frequencies of B6 and
Cd25/ T cells in the 50:50 chimeras were essentially identical
(Figure 6E). Thus, our results indicated that lack of CD25 did not
impair CD4+ T cell development but did promote the differentia-
tion of Tfh cells.
DISCUSSION
Our data show that the availability of IL-2 regulates the differen-
tiation of Tfh cells and thus controls GC formation and long-lived
Figure 4. Inhibition of the GC B Cell Response after rIL-2 Treatment Does Not Require FoxP3+ Treg Cells
FoxP3-DTR mice were infected with PR8, administered PBS or DT on days 0, 4, and 7 after infection, or received DT on days 0, 4, and 7 after infection together
with 30,000 U of human recombinant rIL-2 twice a day starting 3 days after infection. Cells from the mLN were analyzed on day 10.
(A and B) The percentage of CD4+ T cells that expressed FoxP3 (A) and the percentage of CD19+ B cells with a FAS+PNA+ GC phenotype (B) were determined by
flow cytometry.
(C) The number of FAS+PNA+GCBcells was calculated. Data are representative of two independent experiments (mean ± SDof fivemice per time point). p values
were determined by two-tailed Student’s t test.
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Tfh cells are suppressed, GCs do not form, and influenza-
specific IgG responses are reduced. Importantly, the lack of
germinal center B cells in IL-2-treatedmice is not a consequence
of IL-2 signaling in B cells, but is the result of IL-2 signaling in
T cells, which impairs Tfh cell differentiation. Moreover, although
IL-2 signaling promotes the accumulation of Treg cells, which
could suppress Tfh cells and GCs, Treg cells are not required
for the ability of IL-2 to repress Tfh cell differentiation. Thus,
our results demonstrate that IL-2 fine-tunes the balance of T
effector cell and B cell helper aspects of the immune response
to influenza.
An important functional consequence of impaired Tfh cell
differentiation is the reduced number of GC B cells and influ-
enza-specific IgG-secreting cells. Although we cannot easily
measure the affinity of the influenza-specific antibody produced
in IL-2-treated mice, we anticipate that the antibodies that are
produced would be of low affinity because of lack of selection
in the GC. Moreover, in addition to reductions in long-lived, influ-
enza-specific IgG-secreting cells in the BM, we would also
anticipate that there would be defects in the generation of influ-
enza-specific memory B cells, because both of these cell types
are also thought to depend on events that occur in the GC. Thus,
the ability of IL-2 to repress Tfh cell differentiation has multiple
effects on the humoral immune response to influenza.
IL-2 is often perceived as a T cell growth factor for both CD4+
and CD8+ T cells (Malek, 2008). However, both CD4+ and CD8+
T cells respond to antigen and proliferate in mice lacking IL-2 or
its receptor (Bachmann et al., 1995; Malek and Bayer, 2004;
Williams et al., 2006). In fact, IL-2-deficient mice develop autoim-
munity as a result of excessive effector T cell responses (Sadlack
et al., 1993, 1995; Suzuki et al., 1995). This phenomenon can beattributed, in part, to poor Treg cell survival in the absence of IL-2
signaling (de la Rosa et al., 2004; Malek et al., 2002). Although
Treg cells clearly have the ability to impair CD4 T cell responses
and even B cell responses (Alexander et al., 2011; Chung et al.,
2011; Linterman et al., 2011), the role of IL-2 in preventing Tfh cell
differentiation and GC formation does not appear to be depen-
dent on Treg cells. Despite the presence of higher numbers
of Treg cells in IL-2-treated mice, IL-2 still suppresses GC
formation when Treg cells are eliminated. Moreover, only
Cd25+/+ Tfh cells are suppressed by the addition of IL-2 in
B6:Cd25/ chimeric mice, despite the equal opportunity of
Treg cells to interact with both B6 and Cd25/ T cells. Thus,
IL-2 acts directly on differentiating Tfh precursor cells, rather
than indirectly via Treg cell-mediated suppression.
The transcription factor Blimp1 controls the terminal differen-
tiation of B cells into antibody-secreting plasma cells. As part of
this pathway, Blimp1 represses the expression of Bcl6 (Johnston
et al., 2009). Similarly, Blimp1 represses Bcl6 expression in
T cells and promotes their terminal differentiation into effector
cells (Crotty, 2011; Fazilleau et al., 2009; Poholek et al., 2010).
Of course, impaired Bcl6 expression in T cells would also
preclude the differentiation of Tfh cells (Johnston et al., 2009;
Nurieva et al., 2009; Yu et al., 2009). Conversely, Bcl6 overex-
pression represses Blimp1 and favors Tfh cell development
(Johnston et al., 2009). Thus, the balance between Blimp1 and
Bcl6 expression is thought to control the relative commitment
of CD4 T cells to effector or Tfh cell pathways (Crotty, 2011;
Choi et al., 2011).
Interestingly, Blimp1 expression is increased in response to
IL-2 (Gong and Malek, 2007). Thus, we speculate that one way
in which IL-2 signaling impairs Tfh cell responses to influenza
is by altering the Blimp1:Bcl6 ratio. This view is in agreementImmunity 36, 847–856, May 25, 2012 ª2012 Elsevier Inc. 851
Figure 5. rIL-2 Impairs the Tfh Cell Response to Influenza
(A) B6micewere infectedwith PR8 and the expression of Bcl6 and ICOSwas evaluated onPD-1hiCXCR5hiCD4+ T cells and PD-1loCXCR5loCD4+ T cells on day 10.
(B–D) B6 mice were infected with PR8, treated with 30,000 U of human rIL-2 or PBS twice a day starting 3 days after infection, and cells from the mLNs were
analyzed by flow cytometry on day 10.
(B) The expression of Bcl6 in CD4+ T cells was evaluated.
(C) The percentage of CD4+ T cells with a CXCR5hiPD-1hi Tfh cell phenotype was determined.
(D) The number of CXCR5hiPD-1hi Tfh cells was calculated.
(E and F) B6micewere infectedwith PR8 and treatedwith 30,000U of human rIL-2 or PBS twice a day starting 3 days after infection, and cells from themLNswere
analyzed by flow cytometry on day 6.
(E) The percentage of CD4+ T cells with a CXCR5hiPD-1hi Tfh cell phenotype was determined.
(F) The number of CXCR5hiPD-1hi Tfh cells was calculated.
(G) Bcl6, ICOS, and CD25 expression was evaluated on PD-1hiCXCR5hi NP-specific CD4+ T cells and PD-1loCXCR5lo NP-specific CD4+ T cells.
(H) The expression of Bcl6 in NP-specific CD4+ T cells was evaluated.
(I) The percentage of NP-specific CD4+ T cells with a CXCR5hiPD-1hi Tfh cell phenotype was determined.
(J) The number of NP-specific CXCR5hiPD-1hi Tfh cells was calculated.
(K) The number of NP-specific CXCR5loPD-1lo effector CD4+ T cells was calculated.
(L) The expression of Bcl6 on CD4+CXCR5+PD-1hi cells and NP-specific CD4+CXCR5+PD-1hi cells from IL-2-treated and control mice was evaluated by flow
cytometry.
Data are representative of four independent experiments (mean ± SD of five mice per group). p values were determined by two-tailed Student’s t test.
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Bcl6 are reciprocally expressed in CD25hi and CD25lo CD4+
T cells responding to LCMV (Choi et al., 2011). Therefore, we852 Immunity 36, 847–856, May 25, 2012 ª2012 Elsevier Inc.suggest that prolonged IL-2 signaling leads to increased Blimp1
expression and represses Bcl6 expression and thus impairs the
differentiation or maintenance of Tfh cells. Interestingly, our data
Figure 6. IL-2 Signaling Directly Inhibits Tfh Cell Responses to Influenza
(A and B) B6 mice were irradiated and reconstituted with a 50:50 mix of BM from wild-type CD45.1 donors and Cd25/ donors (CD45.2). Reconstituted mice
were infectedwith PR8 and treated daily with 30,000 U of rIL-2 starting 3 days after infection, and cells from themLNswere analyzed on day 10. The percentage of
CD45.1+ or CD45.2+ CD4+CXCR5+PD-1hi Tfh cells (A) and NP-specific CD45.1+ or CD45.2+ CD4+CXCR5+PD-1hi Tfh cells (B) was determined. Data were pooled
from three independent experiments (mean ± SD). Representative plots gated on CD4+ T cells are shown.
(C and D) B6 mice were irradiated and reconstituted with a 50:50 mix of BM from wild-type CD45.1 donors and Cd25/ donors (CD45.2). Reconstituted mice
were infected with PR8, and cells from the mLNs were analyzed on day 10. The percentage of CD45.1+ or CD45.2+ CD4+CXCR5+PD-1hi Tfh cells (C) and NP-
specific CD45.1+ or CD45.2+ CD4+CXCR5+PD-1hi Tfh cells (D) was determined.
(E) The percentage of CD45.1+ or CD45.2+ total CD4+ T cells was determined. Plot is gated on CD4+ T cells. Data were pooled from three independent
experiments (mean ± SD). Representative plots gated on CD4+ T cells are shown. p values were determined by two-tailed Student’s t test.
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a corresponding increase in the number of effector CD4+ T cells.
These results suggest that IL-2 signaling compromises themain-
tenance or survival of T cells committed to the Tfh cell pathway,
rather than diverting influenza-specific CD4+ T cells from the Tfh
cell pathway into the Th1 effector cell pathway.
Published results show that IL-2 controls the differentiation of
T cells by regulating the expression of a variety of transcription
factors (Pipkin et al., 2010). For example, IL-2 represses RORgt
in CD4 T cells and prevents their differentiation into Th17 cells
(Chen et al., 2011; Laurence et al., 2007; Pandiyan et al.,
2011). IL-2 and STAT5 are also negative regulators of BCL6 in
CD8+ T cells and consequently, IL-2 signaling promotes the
expansion of effector CD8+ T cells at the expense of memory
CD8+ T cells (Kalia et al., 2010; Pipkin et al., 2010). Similarly,
STAT5 inhibits the differentiation of Tfh cells via the BLIMP-1-
dependent repression of BCL6 (Johnston et al., 2012). Consis-
tent with this idea, we suggest that IL-2 signaling impairs or
prevents Bcl6 expression in primed CD4+ T cells, possibly via
a STAT5-dependent mechanism (Johnston et al., 2012), andprevents their subsequent differentiation into Tfh cells. In the
absence of Bcl6, Tfh cell precursors do not express CXCR5,
do not home to the T cell area, and do not receive the necessary
signals from B cells to be maintained as Tfh cells (Choi et al.,
2011; Deenick et al., 2011; Good-Jacobson et al., 2010). In
contrast, once CD4+ T cells have differentiated into Tfh cells,
they lose CD25 expression and the addition of IL-2 does not
affect Bcl6 or CXCR5 expression. Thus, we believe that IL-2
acts early in the Tfh cell differentiation pathway.
One of the hallmarks of Tfh cells is the expression of high levels
of PD-1 (Yu and Vinuesa, 2010). PD-1 is an inhibitory receptor
that is often associated with T cell exhaustion (Sharpe et al.,
2007). However, PD-1 is also required for Tfh cell function and
for germinal center formation (Good-Jacobson et al., 2010).
However, it is not clear how PD-1 contributes to Tfh cell differen-
tiation or maintenance. Interestingly, PD-1 signaling inhibits IL-2
production (Chikuma et al., 2009). Based on our observations
showing that IL-2 signaling is deleterious to Tfh cell responses,
we speculate that PD-1 signaling may promote the maintenance
of Tfh cells by blocking autocrine IL-2 production.Immunity 36, 847–856, May 25, 2012 ª2012 Elsevier Inc. 853
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IL-2 Limits Tfh Cell and Germinal Center FormationCollectively, our results demonstrate that IL-2 plays a central
role in the control of the Tfh cell response to influenza. Our find-
ings also offer a new perspective for how Tfh cell development is
regulated and demonstrate that the physiological availability of
IL-2 is a critical factor that regulates successful B cell responses
in vivo.
EXPERIMENTAL PROCEDURES
Mice, Infections, and In Vivo Treatments
C57BL/6 (B6), B6.129S4-Il2ratm1Dw/J(Cd25/), and B6.IgHa.Thy-1a.Ptrpca
(CD45.1) mice were originally obtained from Jackson Laboratories and were
bred in the University of Rochester animal facility. B6.129S6-Foxp3tm1DTR
(FoxP3-DTR) mice were obtained from A. Rudensky (Memorial Sloan-Ketter-
ing Cancer Center). Influenza virus infections were performed intranasally
with 500 egg infectious units of A/PR8/34 (PR8) in 100 ml of PBS. Heligmoso-
moides polygyrus (Hp) infections were performed by gavage with 200 L3 Hp
larvae as described (Wojciechowski et al., 2009). BM chimeric mice were
generated by lethally irradiating CD45.1 mice with 950 Rads from a 137Cs
source delivered in two equal doses 4–5 hr apart. After irradiation, mice
were intravenously injected with 5 3 106 total BM cells and allowed to recon-
stitute for 8–12 weeks before influenza infection. In indicated experiments, WT
and FoxP3-DTR mice received an intraperitoneal injection of 50 mg/kg of DT
(Sigma) on days 0, 4, and 7 after infection. For IL-2 treatment, mice were intra-
peritoneally administered 30,000 U of recombinant human IL-2 (National
Cancer Institute) twice a day starting 3 days after infection. Control mice
received injections of PBS. All experimental procedures involving animals
were approved by the University of Rochester University Committee on Animal
Resources and were performed according to guidelines outlined by the
National Research Council.
Cell Preparation and Flow Cytometry
Cell suspensions from mLNs were centrifuged, resuspended in 150 mM
NH4Cl, 10 mM KHCO3, 0.1 mM EDTA for 10 min to lyse red cells, and filtered
through a 70 mm nylon cell strainer (BD Biosciences). Cells were washed and
resuspended in PBS with 5% donor calf serum and 10 mg/ml FcBlock (2.4G2;
Trudeau Institute) for 10 min on ice followed by staining with fluorochrome-
conjugated antibodies or tetramer reagents. The IAbNP311-325 MHC class II
tetramer was obtained from the NIH Tetramer Core Facility. Fluorochrome-
labeled anti-CD45.1 (A20), anti-CD45.2 (104), anti-PD-1 (J43), anti-FoxP3
(FJK-16 s), anti-CD19 (1D3), anti-B220 (RA3-6B2), and anti-CD138 (281.2)
were from eBioscience. Anti-Bcl6 (K112.91), anti-CXCR5 (2G-8), anti-ICOS
(7E.17G9), anti-CD4 (RM4-5), and anti-CD95 (RM4-5) were from BD Biosci-
ences. Peanut agglutinin (PNA) was obtained from Sigma (L7381; Sigma)
and conjugated with FITC. Intracellular staining was performedwith themouse
regulatory T cell staining kit (eBioscience) according to the manufacturer’s
instructions. Flow cytometry was performed with a FACSCanto II (BD Biosci-
ences) or a C6 Flow Cytometer (Accuri) available through the Flow Cytometry
Core Facility at the University of Rochester.
Immunofluorescence
Lymph nodes were frozen in OCT (Tissue-Tek; Sakura) and 7 mm frozen
sections were prepared and stained as described (Rangel-Moreno et al.,
2011). Slides were probed for 30 min at 25C with anti-B220 (RA3-6B2),
anti-IgDb (2170-170) obtained from BD Biosciences, anti-CD21 (7E9, BioLe-
gend), and PNA (L7381; Sigma). Biotin-conjugated primary antibodies were
detected with streptavidin-Alexa Fluor 555 (S21381; Invitrogen Life Sciences).
Images were obtained with a Zeiss Axioplan 2 microscope with a Zeiss Axio-
cam digital camera (Zeiss) and saved as TIFF files.
ELISAs and ELISPOT
For ELISAs, 96-well plates were coated with purified viral proteins (Lee et al.,
2005) at 1 mg/ml in 0.05 M Na2CO3 (pH 9.6) overnight and then blocked for 1 hr
with 1% BSA in PBS. Serum samples were serially diluted (3-fold) in PBS with
10 mg/ml BSA and 0.1% Tween 20 before incubation on coated plates. After
washing, bound antibody was detected with HRP-conjugated goat anti-
mouse IgG1 (Southern Biotechnology Associates). For ELISPOT, multiscreen854 Immunity 36, 847–856, May 25, 2012 ª2012 Elsevier Inc.cellulose filter plates (Millipore) were coated overnight with 1 mg/ml purified
viral proteins. Cells were collected from bone marrow and plated in triplicate
starting at 1 3 106/well and in 3-fold serial dilutions in complete RPMI 1640
containing 10% FBS. After 5 hr, the wells were washed with PBS containing
0.5%BSA and 0.05% Tween 20, and IgGwas detected with alkaline phospha-
tase-conjugated goat anti-mouse IgG (Southern Biotechnology Associates).
Spots were automatically counted in a CTL-immunoSpot S5 analyzer.
NP-Tetramer Preparation for Detection of Influenza-Specific B Cells
The coding sequence of NP from the A/PR8/34 virus was synthesized in-frame
with the coding sequence for a 15 amino acid biotinylation consensus site
(Beckett et al., 1999) on the 30 end (GeneArt, Regensburg, Germany). The
modified NP sequence was cloned in-frame to the 63 His tag in the pTRC-
His2c expression vector (Invitrogen, Carlsbad, CA). NP protein was expressed
in E. coli strain Ultra BL21 (DE3) (EdgeBio, Gaithersburg, MD) and purified by
FPLC with a HisTrap HP Column (GE Healthcare). Purified protein was
biotinylated by addition of Biotin-protein ligase (Avidity, Aurora, CO). The
biotinylated NP protein was then tetramerized with PE-labeled streptavidin
(Prozyme, Hayward, CA). Labeled tetramers were purified by size exclusion
on a HiPrep 16/60 Sephacryl S-300 column (GE Healthcare, Piscataway, NJ).
Statistical Analysis
The statistical significance of differences in mean values was analyzed by
a two-tailed Student’s t test. p values of less than 0.05 were considered
statistically significant.
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